Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development
US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ:...
Royal Philips and Suzhou Peixin Collaborate on AI-Powered Interventional Therapy Platform for Structural Heart Disease
Dutch device giant Royal Philips (NYSE: PHG) and China-based Suzhou Peixin Technology Co., Ltd. late...
YolTech Therapeutics Receives NMPA Clearance for YOLT-101 in HeFH Clinical Study
Shanghai-based YolTech Therapeutics announced that it has received clearance from the National Medical Products Administration...
CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a favorable outcome in the opposition proceedings...
Eisai Announces Commercial Release of Urece (Dotinurad) from Suzhou Facility in China
Japan-based Eisai (TYO: 4523) announced the official commercial release of the first batch of its...
InnoCare Pharma Receives FDA Approval for Mesutoclax in Myeloid Malignancies
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical trial...
Pfizer and Astellas’ Xtandi Shows Positive Results in Phase III EMBARK Study for Prostate Cancer
Partners Pfizer (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced positive topline results from...
Bayer’s Elinzanetant Granted UK Marketing Authorization for Menopause-Related Vasomotor Symptoms
Germany’s Bayer (ETR: BAYN) this week announced that the UK Medicines and Healthcare products Regulatory...
AbbVie Licenses IGI Therapeutics’ ISB 2001 for Oncology and Autoimmune Diseases
US-based AbbVie (NYSE: ABBV) this week announced a licensing agreement with IGI Therapeutics SA, a...
Jiangsu Jibeier Receives NMPA Approval for Clinical Trials of JJH201601 Liposome in Advanced HNSCC
China-based Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566) announced that it has received clinical approval...
Fosun Pharmaceutical Launches Phase III Study for Fumaining in Pediatric Low-Grade Glioma
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the initiation of a...
BeOne Medicines’ Tevimbra Approved by European Commission for Nasopharyngeal Carcinoma
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...
Johnson & Johnson MedTech Launches VARIPULSE Platform for Atrial Fibrillation in Asia-Pacific
US major Johnson & Johnson MedTech announced the launch of its VARIPULSE Platform in the...
JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca’s Alexion for JUST-AAV Gene Therapy Platform
Japan-based JCR Pharmaceuticals Co., Ltd. (TYO: 4552) announced a licensing agreement with UK-based AstraZeneca’s (NASDAQ:...
Zhimeng Biopharma’s CB03-154 Receives CDE Approval for ALS Phase II/III Clinical Study
China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II/III clinical study...
NHSA Finalizes 2025 Drug Catalog Adjustment Plan with Minimal Changes from Draft
The National Healthcare Security Administration (NHSA) this week issued the finalized “2025 National Basic Medical...
MSD’s Once-Daily HIV-1 Therapy Doravirine/Islatravir NDA Accepted by FDA for Review
Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration...
Zelgen’s ZG006 Receives Breakthrough Therapy Designation for Advanced Small Cell Lung Cancer
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received breakthrough therapy...
Cosunter’s GST-HG131 Granted Breakthrough Therapy Designation for HBV Treatment in China
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced that it has received breakthrough therapy...
Ascentage Pharma’s Lisaftoclax Receives NMPA Approval for CLL/SLL Treatment
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that it has received conditional marketing approval...